BioSpace News Archive

Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 2023 Jefferies London Healthcare Conference. Gerald Herman, Executive Vice President & Chief Financial Officer will present and participate in an analyst moderated question and answer session on behalf of the Company on Tuesday, November 14, 2022 at 8:30 AM GMT (3:30 AM Eastern Time).

The hope has always been that genetic testing can lead to not only better health care but also to preventing many health problems in the first place.

Boston Pharmaceuticals announced it will present new data supporting its long-acting dosing schedule and an analysis of treatment in diabetic sub-groups from the Phase 2a Part A clinical program evaluating BOS-580 for the treatment of non-alcoholic steatohepatitis, at the American Association for the Study of Liver Diseases The Liver Meeting®, taking place November 10-14, 2023, in Boston.

Revolo Biotherapeutics announced that new preclinical data on ‘1805 will be presented via two posters at the American College of Rheumatology Convergence 2023 Annual Conference, which is being held November 10–15 at the San Diego Convention Center in San Diego, CA.

Discovery Life Sciences, the Biospecimen and Biomarker Specialists, announced the appointment of Greg Herrema as its new chief executive officer.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced data from the Phase 2a IRIS-RA clinical study for the treatment of adults living with moderate to severe active rheumatoid arthritis who have tested positive for anti-citrullinated protein antibodies a and/or rheumatoid factor, and who have had an inadequate response or intolerance to at least one anti-tumor necrosis factor therapy.

Immunovia, the diagnostics company focused on early detection of pancreatic cancer, announced the successful completion of the discovery phase for the Company’s next-generation test.

Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing a first-in-class small molecule ChemR23 agonist to treat cancer and autoimmune diseases small molecule (TP-317) to treat cancer and autoimmune diseases

GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, announced that Ty Atteberry has joined the company as Vice President of Sales.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing cutting-edge vaccines, therapeutics, and drug delivery technologies against cancer and other diseases